Follow Our Live Coverage of COVID-19 Developments

Two-Drug Combination Approved for High Blood Pressure

Eased hypertension better than either drug alone, maker says

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Jan. 21, 2008 (HealthDay News) -- Tekturna HCT -- a combination of the drug Tekturna (aliskiren) and the diuretic hydrochlorothiazide -- has been approved by the U.S. Food and Drug Administration to treat high blood pressure, maker Novartis AG said Monday.

Clinical testing found the combination tablet "offers greater blood pressure reductions that either component alone," the drug maker said in a statement.

Approved last March, Tekturna inhibits rennin, an enzyme responsible for hypertension. The second drug, a diuretic, helps rid the body of excess water and salt.

Tektruna HCT will be available in early February, Novartis said. The most common adverse effects reported include dizziness, flu-like symptoms, diarrhea, cough and tiredness.

More information

The FDA has more about Tekturna.


Last Updated: